This page includes quick summaries of the available therapeutics.
Providers must review the respective medication Fact Sheets.
Updates
Please review the latest information released by the county:
- Therapeutics update 12/30/2021
- Therapeutics update 01/06/2022
- Therapeutics update 02/14/2022
- CDPH Therapeutics update 03/30/2022
- Therapeutics update 04/05/2022
- Paxlovid Prescribing Resources Update 05/05/22
Pre-exposure prophylaxis (PrEP)
Evusheld
AstraZeneca’s Evusheld (Tixagevimab co-packaged with Cilgavimab)
Type: A combination of two long-acting anti-SARS-CoV-2 monoclonal antibodies for Pre-Exposure Prophylaxis.
Administration Route: Intramuscular (IM) – for pre-exposure prophylaxis against COVID-19.
Timing: Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2.
Target Population: For individuals who have moderate to severe immunocompromised states and are not expected to mount an adequate response to vaccination or individuals for whom COVID-19 vaccination is contraindicated due to severe adverse reaction to vaccine. Must be at high risk for progression to severe COVID-19 symptoms.
Monoclonal Treatment
Sotrovimab
GSK’s Sotrovimab
Type: Monoclonal Antibody
Administration Route: Intravenous – one time infusion treatment for mild to moderately-ill outpatients.
Timing: As soon as possible after diagnosis of COVID-19 and within 7 days of symptom onset.
Target Population: COVID-19 patients 12 years of age and older weighing at least 40 kg who are at high risk for progression to severe COVID-19 symptoms.
Data from the Centers for Disease Control and Prevention (CDC) released March 29, 2022 show that the BA.2 variant is now circulating with a frequency exceeding 50% in California. Results from in vitro assays that are used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that Sotrovimab is not fully active against the BA.2 variant. As of 3/30/22, the FDA has de-authorized use of Sotrovimab in California.
- Sotrovimab EUA Fact Sheet (updated 3/25/22 to reflect new data using authentic live BA.2 virus)
- Sotrovimab EUA Letter
- Fact Sheet for Patient/Caregivers
- Fact Sheet for Patient/Caregivers (Spanish)
Bebtelovimab
Eli Lilly’s Bebtelovimab
Type: Monoclonal Antibody
Administration Route: Intravenous Injection – one-time, intravenous injection over 30 seconds.
Timing: As soon as possible after diagnosis of COVID-19 and within 7 days of symptom onset.
Target Population: COVID-19 patients 12 years of age and older weighing at least 40 kg who are at high risk for progression to severe COVID-19 symptoms for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
Oral Treatment
Paxlovid
Pfizer’s Paxlovid
Type: Oral antiviral – protease inhibitor.
Administration Route: By mouth (PO) – twice daily for 5 days.
Timing: As soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.
Target Population: COVID-19 patients 12 years of age and older weighing at least 40 kg who are at high risk for progression to severe COVID-19 symptoms. Many drug-drug interactions.
Lagevrio (Molnupiravir)
Merck and Ridgeback’s Molnupiravir
Type: Oral antiviral – nucleoside analogue.
Administration Route: By mouth (PO) – every 12 hours for 5 days
Timing: As soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.
Target Population: COVID-19 patients 18 years of age and older who are at high risk for progression to severe COVID-19 symptoms. NOT recommended in pregnancy.
How to obtain COVID-19 Therapeutics
Sotrovimab: As of 3/30/22, the FDA has de-authorized use of Sotrovimab in California.
Evusheld: At this time, providers must be reviewed and approved by the Medical Health Operational Area Coordinator (MHOAC). If approved by the MHOAC as an administering site, providers will register in the Health Partner Ordering Portal (HPOP) to receive Evusheld. To become a provider please email COVIDTherapeutics@ventura.org.
Paxlovid and Molnupiravir: When prescribing these medications to your patients, providers should visit the HHS Therapeutics Locator to find pharmacies with current supply of these products. Patients may also be advised of the HHS Test to Treat (T2T) program and the HHS T2T Locator map.
Bebtelovimab: At this time, providers must be reviewed and approved by the Medical Health Operational Area Coordinator (MHOAC). If approved by the MHOAC as an administering site, providers will register in the Health Partner Ordering Portal (HPOP) to receive Bebtelovimab. To become a provider please email COVIDTherapeutics@ventura.org.
Reporting Requirements
